REVIEW ARTICLE
The role of carbonic anhydrase IX in hypoxia control in OSCC
Mario Pérez-Sayáns,
Claudiu T. Supuran,
Silvia Pastorekova,
José Manuel Suárez-Peñaranda,
Gayoso-Diz Pilar,
Francisco Barros-Angueira,
José Manuel Gándara-Rey,
Abel García-García,
Mario Pérez-Sayáns
Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
Search for more papers by this authorClaudiu T. Supuran
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Sesto Fiorentino (Firenze), Italy
Search for more papers by this authorSilvia Pastorekova
Institute of Virology, Slovak Academy of Sciences
Search for more papers by this authorJosé Manuel Suárez-Peñaranda
Servicio de Anatomia Patológica, Hospital Clinico Universitario de Santiago, Choupana s/n Santiago de Compostela, Spain
Search for more papers by this authorGayoso-Diz Pilar
Clinical Epidemiology and Biostatistics Unit, Hospital Clínico Universitario de Santiago de Compostela, Spain
Search for more papers by this authorFrancisco Barros-Angueira
Unidad de Medicina Molecular – Fundación Pública Galega de Medicina Xenómica, Edificio de Consultas planta, Hospital Clinico Universitario C.P. Santiago de Compostela, Spain
Search for more papers by this authorJosé Manuel Gándara-Rey
Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Entrerríos s/n, Santiago de Compostela, Spain
Search for more papers by this authorAbel García-García
Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
Search for more papers by this authorMario Pérez-Sayáns,
Claudiu T. Supuran,
Silvia Pastorekova,
José Manuel Suárez-Peñaranda,
Gayoso-Diz Pilar,
Francisco Barros-Angueira,
José Manuel Gándara-Rey,
Abel García-García,
Mario Pérez-Sayáns
Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
Search for more papers by this authorClaudiu T. Supuran
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Sesto Fiorentino (Firenze), Italy
Search for more papers by this authorSilvia Pastorekova
Institute of Virology, Slovak Academy of Sciences
Search for more papers by this authorJosé Manuel Suárez-Peñaranda
Servicio de Anatomia Patológica, Hospital Clinico Universitario de Santiago, Choupana s/n Santiago de Compostela, Spain
Search for more papers by this authorGayoso-Diz Pilar
Clinical Epidemiology and Biostatistics Unit, Hospital Clínico Universitario de Santiago de Compostela, Spain
Search for more papers by this authorFrancisco Barros-Angueira
Unidad de Medicina Molecular – Fundación Pública Galega de Medicina Xenómica, Edificio de Consultas planta, Hospital Clinico Universitario C.P. Santiago de Compostela, Spain
Search for more papers by this authorJosé Manuel Gándara-Rey
Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Entrerríos s/n, Santiago de Compostela, Spain
Search for more papers by this authorAbel García-García
Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
Search for more papers by this authorMario Pérez-Sayáns, Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Instituto de Investigación Sanitaria de Santiago (IDIS), Entrerríos s/n, Santiago de Compostela, C.P. 15782 Spain. Tel: +0034626233504, Fax: +0034986295424, E-mail: [email protected]
Abstract
Tumoral microenvironments play a key role in the evolution of solid tumors. Tumor hypoxia is actively involved in the promotion of genetic instability, the invasive capacity of tumor cells, metastasis, and a worsening of the clinical evolution. Endogenous hypoxia markers are controlled by hypoxia-related genes, formed by HIF-1, which is related to several target genes that involve the energy metabolism, angiogenesis, and transmembrane carbonic anhydrases (CAs), mainly CA-IX that is one of the tumor-related carbonic anhydrases. The goal of this paper is to establish the role of CA-IX as a hypoxia marker in OSCC, while analyzing its expression in this type of tumors and its relationship with several clinical and pathological parameters and prognosis, evaluating its relationship with angiogenesis, other hypoxia markers, and clarifying its role in chemotherapy and radiotherapy resistance.
References
- 1Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol2004; 381: 335–54.
- 2Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist2004; 9(Suppl 5): 10–7.
- 3Osinsky S, Zavelevich M, Vaupel P. Tumor hypoxia and malignant progression. Exp Oncol2009; 31: 80–6.
- 4Vaupel P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol2010; 32: 125–7.
- 5Le QT. Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches. Int J Radiat Oncol Biol Phys2007; 2(Suppl): S56–8.
- 6Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer2002; 2: 38–47.
- 7Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev2004; 23: 293–310.
- 8Vigneswaran N, Wu J, Song A, Annapragada A, Zacharias W. Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp Mol Pathol2011; 90: 215–25.
- 9Graeber TG, Osmanian C, Jacks T, et al.Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature1996; 379: 88–91.
- 10Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst2001; 93: 266–76.
- 11Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol2001; 18: 243–59.
- 12Dewhirst MW, Ong ET, Braun RD, et al.Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer1999; 79: 1717–22.
- 13Lutterbach J, Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys2000; 48: 1345–50.
- 14Petersen C, Zips D, Krause M, et al.Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys2001; 51: 483–93.
- 15Overgaard J, Hansen HS, Specht L, et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet2003; 362: 933–40.
- 16Hoogsteen IJ, Marres HA, Bussink J, Van der Kogel AJ, Kaanders JH. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck2007; 29: 591–604.
- 17Hoogsteen IJ, Marres HA, Wijffels KI, et al.Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res2005; 11: 97–106.
- 18Evans SM, Hahn S, Pook DR, et al.Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res2000; 60: 2018–24.
- 19Raleigh JA, Calkins-Adams DP, Rinker LH, et al.Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res1998; 58: 3765–8.
- 20Gleadle JM, Ratcliffe PJ. Hypoxia and the regulation of gene expression. Mol Med Today1998; 4: 122–9.
- 21Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer Lett2011; 313: 1–8.
- 22Gnarra JR, Zhou S, Merrill MJ, et al.Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A1996; 93: 10589–94.
- 23Lal A, Peters H, St Croix B, et al.Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst2001; 93: 1337–43.
- 24Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell1996; 86: 353–64.
- 25Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem2011; 3: 1165–80.
- 26Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov2011; 10: 767–77.
- 27Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov2008; 7: 168–81.
- 28Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett2010; 20: 3467–74.
- 29Vullo D, Franchi M, Gallori E, et al.Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett2003; 13: 1005–9.
- 30Vullo D, Innocenti A, Nishimori I, et al.Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?. Bioorg Med Chem Lett2005; 15: 963–9.
- 31Ivanov S, Liao SY, Ivanova A, et al.Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol2001; 158: 905–19.
- 32Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol2003; 67: 3–15.
- 33Brewer CA, Liao SY, Wilczynski SP, et al.A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol1996; 63: 337–44.
- 34Giatromanolaki A, Koukourakis MI, Sivridis E, et al.Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res2001; 61: 7992–8.
- 35Klatte T, Belldegrun AS, Pantuck AJ. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int2008; 101(Suppl 4): 45–8.
- 36Chia SK, Wykoff CC, Watson PH, et al.Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol2001; 19: 3660–8.
- 37Turner JR, Odze RD, Crum CP, Resnick MB. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol1997; 28: 740–4.
- 38Saarnio J, Parkkila S, Parkkila AK, et al.Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA-IX, with potential value as a marker of cell proliferation. Am J Pathol1998; 153: 279–85.
- 39Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM, Garcia-Garcia A. Genetic and molecular alterations associated with oral squamous cell cancer (Review). Oncol Rep2009; 22: 1277–82.
- 40Choi SW, Kim JY, Park JY, Cha IH, Kim J, Lee S. Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol2008; 39: 1317–22.
- 41Roh JL, Cho KJ, Kwon GY, et al.The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol2009; 45: 63–8.
- 42Oliveira LR, Ribeiro-Silva A. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg2011; 40: 298–307.
- 43Eckert AW, Lautner MH, Schutze A, Taubert H, Schubert J, Bilkenroth U. Coexpression of hypoxia-inducible factor-1alpha and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology2011; 58: 1136–47.
- 44Kondo Y, Yoshikawa K, Omura Y, et al.Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma. Oncol Rep2011; 25: 1227–33.
- 45Eckert AW, Lautner MH, Schutze A, et al.Co-expression of Hif1alpha and CA-IX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med2010; 39: 313–7.
- 46Kim SJ, Shin HJ, Jung KY, et al.Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol2007; 37: 812–9.
- 47Koukourakis MI, Giatromanolaki A, Sivridis E, et al.Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res2001; 7: 3399–403.
- 48Le QT, Kong C, Lavori PW, et al.Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys2007; 69: 167–75.
- 49Kaanders JH, Wijffels KI, Marres HA, et al.Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res2002; 62: 7066–74.
- 50Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer2007; 121: 1813–20.
- 51Brockton N, Dort J, Lau H, et al.High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int J Radiat Oncol Biol Phys2011; 80: 249–57.
- 52Kong CS, Narasimhan B, Cao H, et al.The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys2009; 74: 553–61.
- 53Jonathan RA, Wijffels KI, Peeters W, et al.The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol2006; 79: 288–97.
- 54Beasley NJ, Wykoff CC, Watson PH, et al.Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res2001; 61: 5262–7.
- 55Bhattacharya A, Toth K, Mazurchuk R, et al.Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res2004; 10: 8005–17.
- 56Bhattacharya A, Toth K, Durrani FA, et al.Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia2008; 10: 857–65.
- 57Chintala S, Toth K, Cao S, et al.Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol2010; 66: 899–911.
- 58Zheng G, Zhou M, Ou X, et al.Identification of carbonic anhydrase 9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells. FEBS J2010; 277: 4506–18.
- 59Schmitt A, Barth TF, Beyer E, et al.The tumor antigens RHAMM and G250/CA-IX are expressed in head and neck squamous cell carcinomas and elicit specific CD8 + T cell responses. Int J Oncol2009; 34: 629–39.
- 60Eriksen JG, Overgaard J, Danish Head; Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA-IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol2007; 83: 383–8.
- 61Koukourakis MI, Bentzen SM, Giatromanolaki A, et al.Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol2006; 24: 727–35.
- 62Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A2000; 97: 4748–53.
- 63Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG. Assignment of the hypoxia-inducible factor 1alpha gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics1996; 34: 437–9.
- 64Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med2003; 9: 677–84.
- 65Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol1999; 15: 551–78.
- 66Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki T. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci2005; 96: 394–402.
- 67Zhu GQ, Tang YL, Li L, et al.Hypoxia inducible factor 1alpha and hypoxia inducible factor 2alpha play distinct and functionally overlapping roles in oral squamous cell carcinoma. Clin Cancer Res2010; 16: 4732–41.
- 68Winter SC, Shah KA, Han C, et al.The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer2006; 107: 757–66.
- 69De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA-IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/−chemotherapy. BMC Cancer2005; 5: 42.
- 70Winter SC, Shah KA, Campo L, et al.Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res2005; 11: 7614–20.
- 71Le QT, Shi G, Cao H, et al.Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol2005; 23: 8932–41.
- 72Silva P, Slevin NJ, Sloan P, et al.Use of multiple biological markers in radiotherapy-treated head and neck cancer. J Laryngol Otol2010; 124: 650–8.
- 73Gee HE, Camps C, Buffa FM, et al.Hsa-Mir-210 is a Marker of Tumor Hypoxia and a Prognostic Factor in Head and Neck Cancer. Cancer2010; 116: 2148–58.
- 74De SchutterH, Barbe B, Spaepen M, et al.Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA-IX and GLUT-1. Radiother Oncol2006; 80: 143.
- 75Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev2003; 23: 146–89.
- 76Lou Y, McDonald PC, Oloumi A, et al.Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res2011; 71: 3364–76.
- 77Pacchiano F, Carta F, McDonald PC, et al.Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem2011; 54: 1896–902.
- 78Zatovicova M, Jelenska L, Hulikova A, et al.Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des2010; 16: 3255–63.
- 79Chrastina A, Závada J, Parkkila S, et al.Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer2003; 105: 873–81.
- 80Siebels M, Rohrmann K, Oberneder R, et al.A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol2011; 29: 121–6.
